Recent

% | $
Quotes you view appear here for quick access.

Amicus Therapeutics, Inc. Message Board

daleedwards99 7 posts  |  Last Activity: Aug 31, 2015 9:45 AM Member since: May 16, 2014
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • i like this bold quote: Dr. Bruce H. Littman, C.E.O. of PPL, said "with these results PPL has high confidence in the properties of PPL-003 as a topical treatment for dry eye and other inflammatory eye diseases.  To our knowledge, PPL-003 is the only NFkB inhibitor for these indications and we believe that it will differentiate favourably from existing drugs such as Allergan's Restasis (topical cyclosporine 0.05%), the market leader for dry eye, as well as newer agents close to approval or in trials that target only one inflammation mechanism. There is a high medical need as well as significant market potential for safer and more effective treatments." 

  • TORONTO, Aug. 27, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced today that dosing has commenced in a Phase I study of BHV-0223, a glutamate modulating agent

  • Good Lord Above. I'm about to call it quits over here. Is it fairly valued here? I guess so. Jim? are you still involved in this start up? I participated in the last two raises mate. Seems real but is it?

  • TORONTO, Aug. 24, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC
    Market: PTGEF, Canadian Securities Exchange: PBT.U) and Biohaven
    Pharmaceutical Holding Company Limited ("Biohaven") are pleased to announce
    that the United States Food and Drug Administration has completed its review
    of Biohaven's Investigational New Drug Application (IND) for BHV-0223 and
    initial clinical studies in humans may begin. Portage holds 54% equity
    interest in Biohaven.

    Biohaven intends to immediately proceed with a Phase 1 study designed to
    assess the safety, tolerability, and pharmacokinetics of single and multiple
    doses of BHV-0223 in healthy volunteers. Data from this trial will be used to
    design Phase 3 studies in subjects who suffer from treatment-resistant anxiety
    disorders and planned to begin in early 2016.

    BHV-0223 is a glutamate modulating agent formulated using the Zydis® ODT
    fast-dissolve technology under an exclusive worldwide agreement with Catalent.
    The Zydis®orally disintegrating tablet (ODT) fast-dissolve is a unique,
    freeze-dried oral solid dosage form that disperses instantly in the mouth - no
    water is required. With more than 20 products launched in 50 countries,
    Zydis®is the World's best-in-class, ODT technology.Catalent is the industry
    leader for drug development technology. BHV-0223 is also protected by methods
    of use intellectual property licensed from Yale University School of Medicine.

    BHV-0223 is being developed for eventual commercialization in
    treatment-resistant anxiety disorders, focusing initially on Generalized
    Anxiety Disorder (GAD). The mechanism of action of BHV-0223 involves the
    modulation of glutamate. Recent scientific findings have linked a variety of
    central nervous system and other diseases with altered glutamate function.
    These findings suggest that agents that modulate glutamate neurotransmission
    may have therapeutic potential for treating multiple treatment-resistant
    disorders. Potential target indications thought to involve glutam

  • Biohaven has acquired the world-wide intellectual property rights to a
    portfolio of over 300 prodrugs owned by ALS Biopharma, LLC ("ALSBio"). The
    prodrugs covered by the agreement were designed and prepared by Fox Chase
    Chemical Diversity Center, Inc. ("FCCDC") through a research program funded,
    in part, by the U.S. National Institutes of Health, through two peer-reviewed
    Small Business Innovation Research (SBIR) grants awarded to FCCDC. Most of
    the ALSBio prodrugs would be classified as New Molecular Entities (NMEs), and
    the intellectual property rights acquired by Biohaven include all future
    therapeutic indications.

  • and owns some 50 million shares..bless the chap

  • Good quality stuff continues to do well; Galapagos, another conviction idea is now up 50% since the Show, and I would take half of the table, as the outcome of discussions with AbbVie for its lead drug will be binary.

    I would stick with Synergy Pharma, listed in the US, which I think will be taken over. It is moving up, and I like the stock action.
    Portage Biotech looking good as well.

FOLD
14.89-0.02(-0.13%)Sep 3 4:00 PMEDT